Loading...
XNASAYTU
Market cap9mUSD
Dec 24, Last price  
1.50USD
1D
3.45%
1Q
-38.27%
Jan 2017
-99.97%
IPO
-99.99%
Name

Aytu Biopharma Inc

Chart & Performance

D1W1MN
XNAS:AYTU chart
P/E
—
P/S
0.11
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
169.48%
Rev. gr., 5y
61.73%
Revenues
81m
-24.58%
001,750001,7501,75058,929261,7822,562,4453,221,5903,660,0007,320,35727,632,08065,632,00096,669,000107,399,00081,002,000
Net income
-16m
L-7.07%
-48,954-57,173-58,894-60,270-136,802-59,675-57,318-5,578,690-7,723,404-28,180,084-22,508,304-10,187,863-47,166,950-13,620,000-58,290,000-108,780,000-17,050,000-15,844,000
CFO
-1m
L-72.94%
-27,916-44,799-46,631-43,375-64,818-37,849-37,704-5,501,962-6,634,214-10,657,449-13,829,652-15,940,322-13,831,377-28,373,887-25,964,000-28,823,000-5,129,000-1,388,000
Earnings
Feb 05, 2025

Profile

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
URL
https://aytubio.com/
IPO date
Oct 20, 2017
Employees
164
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
81,002
-24.58%
107,399
11.10%
96,669
47.29%
Cost of revenue
78,679
114,940
128,705
Unusual Expense (Income)
NOPBT
2,323
(7,541)
(32,036)
NOPBT Margin
2.87%
Operating Taxes
1,768
(57)
(110)
Tax Rate
76.11%
NOPAT
555
(7,484)
(31,926)
Net income
(15,844)
-7.07%
(17,050)
-84.33%
(108,780)
86.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,467
15,575
11,694
BB yield
-21.44%
-291.45%
-57.65%
Debt
Debt current
4,252
85
3,909
Long-term debt
12,166
15,545
16,453
Deferred revenue
(1,378)
Other long-term liabilities
17,274
13,378
12,810
Net debt
(3,588)
(5,977)
1,002
Cash flow
Cash from operating activities
(1,388)
(5,129)
(28,823)
CAPEX
Cash from investing activities
(329)
(117)
(3,248)
Cash from financing activities
(1,262)
8,871
1,530
FCF
(39,995)
29,861
(21,540)
Balance
Cash
20,006
22,985
19,360
Long term investments
(1,378)
Excess cash
15,956
16,237
14,527
Stockholders' equity
(319,972)
(304,128)
(288,468)
Invested Capital
380,091
323,484
365,558
ROIC
0.16%
ROCE
3.86%
EV
Common stock shares outstanding
5,538
3,340
1,470
Price
2.92
82.50%
1.60
-88.41%
13.80
-86.23%
Market cap
16,171
202.60%
5,344
-73.66%
20,286
-75.90%
EV
12,583
(633)
21,288
EBITDA
10,595
1,274
(21,785)
EV/EBITDA
1.19
Interest
4,792
147,498
Interest/NOPBT
206.28%